Table 7.

Factors impacting OS in HIV-positive patients treated for PCNSL (data in months)

Factors	Median OS ± SE	Median OS ± SE	P
Age ≤ 50 (n = 19) vs. >50 (n = 8)	6.9 ± 3.4	2.7 ± 1.6	NS
CD4 ≥ 50 (n = 8) vs. <50 (n = 17)	6.8 ± 2.8	2.4 ± 1.2	NS
HAART (n = 23) vs. no HAART (n = 4)	6.9 ± 3.5	1.1 ± 0.1	0.001
LDH ≤ 618 (n = 4) vs. >618 (n = 17)	8.7	3.8 ± 1.0	NS
KPS ≥ 70 (n = 15) vs. <70 (n = 11)	8.7 ± 4.1	1.6 ± 0.3	0.012
Histologically confirmed (n = 8) vs. clinically diagnosed (n = 19)	6.9 ± 2.8	3.4 ± 0.9	NS
Tumor size ≤ 3 cm (n = 11) vs. >3 cm (n = 9)	6.8 ± 2.5	2.4 ± 1.6	NS
Number of lesions ≤ 2 (n = 17) vs. >2 (n = 8)	8.7 ± 4.4	3.4 ± 1.5	NS
Received WBRT (n = 11) vs. not (n = 16)	3.4 ± 2.6	4.0 ± 4.2	NS

PCNSL primary CNS lymphoma, HAART highly-active anti-retroviral treatment, LDH lactate dehydrogenase, KPS Karnofsky performance status, WBRT whole brain radiotherapy